New cocktail targets Hard-to-Treat leukemia

NCT ID NCT07311746

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This early-phase trial tests whether combining three drugs—ruxolitinib, cladribine, and venetoclax—can control T-cell prolymphocytic leukemia (T-PLL) that has returned or not responded to prior treatment. The study will enroll 36 adults and primarily monitor safety and side effects. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination of three drugs: ruxolitinib (Jakafi), cladribine (Mavenclad), and venetoclax (Venclexta)
What this could lead to: If successful, this could offer a new treatment option for patients with a rare and aggressive leukemia that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply to all patients. The drug combination may cause significant side effects or fail to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA T-CELL PROLYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.